Shamburg News · 8-K filed Nov 10, 2026, 4:06 PM EST

Dermata Therapeutics Reports Q3 2026 Results and Launch of Tome Foundational Treatment

DRMA · Dermata Therapeutics, Inc.

  • Earnings
  • Materiality: high

Dermata Therapeutics reported results for the quarter ended September 30, 2026, its first quarter of product revenue following the August 25, 2026 launch of Tome Foundational Treatment. Net sales were $74,000 and net loss was $2.8 million, or $0.55 per share, for the quarter. The company stated that its cash resources are expected to fund operations into the first quarter of 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001493152-26-050964.

Written from the filing by Shamburg Markets. Figures are as reported by the company.